


**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

**1. (previously presented):** A method for the treatment of overactive bladder accompanied with neurogenic disorders, which comprises administering an effective amount of an indoline derivative represented by a formula:



wherein in the formula, R represents a saturated or unsaturated aliphatic acyl group which may have as a substituent a hydroxy group, a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, a cycloalkyl group, an aryl group or one or more halogen atoms; a hydroxy lower alkyl group; an aliphatic acyloxyalkyl group; a lower alkyl group which has as a substituent a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, an aryl-substituted lower alkoxycarbonyl group, a carbamoyl group, a mono or di(lower alkyl)-substituted carbamoyl group or a cyano group; an aromatic acyl group which may have as a substituent one or more halogen atoms; a furoyl group or a pyridylcarbonyl group; R<sup>1</sup> represents a cyano group or a carbamoyl group; R<sup>2</sup> represents a lower alkyl group which may have as a substituent a cyano group, an aryl group or one or more halogen atoms; or a pharmaceutically acceptable salt thereof.

2. **(previously presented):** A method for the treatment as claimed in claim 1, which comprises administering an effective amount of (-)-1-(3-hydroxypropyl)-5-((2R)-2-{{2-((2,2,2-trifluoro-ethyl)oxy)phenyl}oxy)ethyl}amino}propyl)-2,3-dihydro-1H-indol-7-carboxamide or a pharmaceutically acceptable salt thereof.

3. **(previously presented):** A method for the treatment as claimed in claim 1, wherein the neurogenic disorder is cerebral infarction, Parkinson's disease, spinal cord involvement, peripheral neurogenic disorder or multiple sclerosis.

4. **(withdrawn):** A method for the treatment as claimed in claim 1, which comprises administering in combination with one or more other agents used for overactive bladder accompanied with neurogenic disorder.

5. **(withdrawn):** A method for the treatment as claimed in claim 4 wherein the other agent used for overactive bladder accompanied with neurogenic disorder is an agent selected from an anticholinergic drug, an anti-anxiety drug, a cholinergic drug, a cholinesterase inhibitor, an antispasmodic drug, an anti-inflammatory drug or an antimicrobial drug.

6. **(previously presented):** A method for the treatment as claimed in claim 2, wherein the neurogenic disorder is cerebral infarction, Parkinson's disease, spinal cord involvement, peripheral neurogenic disorder or multiple sclerosis.

7. **(withdrawn):** A method for the treatment as claimed in claim 2, which comprises administering in combination with one or more other agents used for overactive bladder accompanied with neurogenic disorder.

8. **(withdrawn):** A method for the treatment as claimed in claim 3, which comprises administering in combination with one or more other agents used for overactive bladder accompanied with neurogenic disorder.

9. **(withdrawn):** A method for the treatment as claimed in claim 6, which comprises administering in combination with one or more other agents used for overactive bladder accompanied with neurogenic disorder.

10. **(withdrawn):** A method for the treatment as claimed in claim 7 wherein the other agent used for overactive bladder accompanied with neurogenic disorder is an agent selected from an anticholinergic drug, an anti-anxiety drug, a cholinergic drug, a cholinesterase inhibitor, an antispasmodic drug, an anti-inflammatory drug or an antimicrobial drug.

11. **(withdrawn):** A method for the treatment as claimed in claim 8 wherein the other agent used for overactive bladder accompanied with neurogenic disorder is an agent selected from an anticholinergic drug, an anti-anxiety drug, a cholinergic drug, a cholinesterase inhibitor, an antispasmodic drug, an anti-inflammatory drug or an antimicrobial drug.

12. **(withdrawn):** A method for the treatment as claimed in claim 9 wherein the other agent used for overactive bladder accompanied with neurogenic disorder is an agent selected from an anticholinergic drug, an anti-anxiety drug, a cholinergic drug, a cholinesterase inhibitor, an antispasmodic drug, an anti-inflammatory drug or an antimicrobial drug.

13. **(new):** A method for the treatment as claimed in claim 1, consisting essentially of administering an effective amount of (-)-1-(3-hydroxypropyl)-5-((2R)-2-{[2-(2-{(2,2,2-trifluoro-ethyl)oxy}phenyl)oxy]ethyl}amino)propyl)-2,3-dihydro-1H-indol-7-carboxamide or a pharmaceutically acceptable salt thereof.